Ładuje się......
The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies –CYP2C9 and warfarin as an example
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: Many studies have shown that genetic polymorphisms of the CYP2C9 gene contribute to some of the variability (around 20%) in warfarin dose requirements and therapeutic response to the drug. It is also clear that this effect must be elicited through difference...
Zapisane w:
| Główni autorzy: | , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Blackwell Science Inc
2007
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2000610/ https://ncbi.nlm.nih.gov/pubmed/17298479 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2007.02850.x |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|